Trial Information

Summary: Phase I Multicenter, Dose Escalation Clinical Study of the Safety and Tolerability of Intravenously Administered SNS-032 Injection, A Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients with Advanced B-Lymphoid Malignancies

You have been asked to take part in this research study because you have advanced chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) that has relapsed (returned after initially responding to chemotherapy).  The purpose of this research study is to determine the highest possible dose of the investigational drug SNS-032 that can be given before unmanageable side effects are seen.  Other purposes are to do pharmacokinetics (PK) studies that see how long SNS-032 remains in the blood.  Laboratory tests will also be done to see if there is any changes to biomarkers (proteins in the body that might be associated with CLL or MM).  Your participation in this study is expected to last at least four weeks (one cycle of treatment).  If you are tolerating treatment and your medical condition is not getting worse, you will be able to receive additional cycles of treatment.  After you discontinue treatment, your medical condition will be followed for about 28 days.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: September 2, 2008 at 2:15:06 PM